血动脉质指数与早期发作的中风后抑郁症的关联:一项前性研究
Mingzhu Deng1, Kangping Song2, Guohua He2
1Department of Neurology, The Second People's Hospital of Hunan Province (Brain Hospital of Hunan Province), Changsha, Hunan, China.
Frontiers in psychiatry
|August 11, 2025
概括
血动脉质指数 (AIP) 是早期发作的中风后抑郁症 (PSD) 的独立风险因素. 较高的AIP水平预测了急性缺血性中风后PSD发展的可能性更高.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 脂质代谢 脂质代谢是什么
背景情况:
- 血动脉生成指数 (AIP) 是一种脂质标志物,在心血管疾病中具有预后价值.
- 关于AIP和早期发作的中风后抑郁症 (PSD) 之间的联系的研究是有限的.
研究的目的:
- 研究急性缺血性中风 (AIS) 患者的AIP和早期发病PSD之间的关系.
- 确定AIP是否可以作为早期发病PSD的预测标记.
主要方法:
- 早期发病的PSD是在AIS两周后使用汉密尔顿抑郁量表-17 (HAMD-17) 确定的.
- 斯皮尔曼相关性和后勤回归分析评估了AIP和HAMD-17分数之间的关联.
- 接收器操作特征 (ROC) 曲线分析评估了AIP对早期发病PSD的预测值.
主要成果:
- 在667名患者中,225名 (33.73%) 被诊断为早期发病的PSD.
- AIP与HAMD-17分数呈正相关性 (r=0.567,P<0.001).AIP与HAMD-17分数呈正相关性 (r=0.567,P<0.001).AIP与HAMD-17分数呈正相关性 (r=0.567,P<0.001).
- AIP是早期发病PSD的一个独立风险因素 (OR=1.843,P<0.001),AUC为0.785.
结论:
- 对于早期发病的PSD,AIP是一个重要的独立风险因素.
- AIP可以帮助预防和治疗中风后抑郁症.
相关概念视频
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
01:30Coronary Artery Disease I: Introduction
55
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
55
01:17Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
46
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
46
01:26Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35